Drug Development

Webinar Date/Time: Wed, Mar 26, 2025 1:30 PM EDT

Regulatory clearances and approvals continue as agencies work to disseminate literature, raise awareness, redouble research efforts, and improve the efficacy of clinical trials.

Webinar Date/Time: Fri, Mar 21, 2025 11:00 AM EDT

While the boards of directors of both companies have approved the transaction, it is not expected to close until the second quarter of 2025, as Mayne Pharma’s shareholders must still vote in favor of the acquisition.

The value of outsourcing partnerships for next-gen biotherapeutics rests in the expertise and technologies that service providers bring to the table.

Webinar Date/Time: Thu, Mar 13, 2025 11:00 AM EDT

The collaboration will utilize Genesis’ proprietary AI platform, initially focusing on targets selected by Incyte.

A capsule formulation may offer more consistent and reliable uptake versus a syringe, while being less dependent on food intake.

The AI co-scientist is a multi-agent AI system that can work as a virtual scientific collaborator.

The approval makes Evrysdi the first and only tablet for treating spinal muscular atrophy.

In seeking a data-driven approach to efficient drug development, MMS aims to enhance its capabilities in advanced clinical trial design, innovative statistics, and data science with the acquisition.

Investing in STEM programs for girls in an education setting and then supporting women as they excel in their professional careers is key to ensuring that vital highly skilled personnel are not left behind.

Christian Morello, vice president and head of the Bioconjugates Business Unit at Lonza, looks at what is involved in developing modern ADCs.

While this approval addresses breast cancer, olaparib in combination with durvalumab was approved by the EU in August 2024 for treatment of endometrial cancer.

Feb. 11, 2025 marks the 10th anniversary of the International Day of Women and Girls in Science.

Application of AI/ML technology and a burst of M&A activity look to be shaping the future of the pharma industry.

European biopharma companies are looking beyond GLP-1s.

Increasing API and formulation complexity and new delivery strategies are driving innovations in taste-masking.

Webinar Date/Time: Tues, March 4, 2025 11:00 AM EST

The optimization of processes for the development and manufacture of biopharmaceuticals is pivotal for producing quality products.

The tariffs President Trump wants to levy against Canada and Mexico are on hold, for now, but China has already announced it intends to proceed with retaliatory tariffs against the US.

CDMOs who have integrated technologies can help further the advancement of ADC development.

If the conditions prove optimal, 2025 could be a prosperous year for bio/pharma business deals.

The reduction is expected to be “substantially completed,” the San Diego-based company said, in the second quarter of 2025.

Winners in this year's Pharmapack Awards include both commercial products and innovations that are shaping the future of pharmaceutical packaging.

Webinar Date/Time: Wednesday, February 12th at 11:00 AM EST

Lonza will work with Iconovo to develop spray-dried formulations for an intranasally delivered biologic using a reformulated biologic drug candidate for obesity.

Vanessa Almendro, Elliot Berger, Benjamin McCloud, and Turna Ray go behind the headlines to discuss their ‘wish list’ for the progression of trends in the bio/pharmaceutical industry.

Webinar Date/Time: Thu, Feb 13, 2025 11:00 AM EST

Pharmaceutical Technology chats about the increasing prevalence of challenging APIs in the development pipeline and the hurdles facing formulators and manufacturers as a result of this trend with Jens Schmidt from Lonza.